This Expert Shares What XRP Looks Like for the Coming Months
Carolina posted the chart alongside a direct assessment. “The pattern driving XRP’s surge this year: Accumulation, Manipulation, Distribution (AMD). That same pattern is forming now, following the initial expansion.” She adds that the manipulation phase is happening now, which puts distribution next.
The Pattern That Started It All
The AMD cycle she has been tracking first played out earlier this year. XRP consolidated in an accumulation zone between roughly $1 and $1.30 through June and July.
A manipulation phase followed, briefly pushing the price below $1. Then distribution took over, driving XRP from below $1 to a peak of $1.68 in August. That completed cycle found Carolina’s current thesis. The pattern worked once. Now she sees it forming again.
Where XRP Stands Now
After the August peak, a second AMD cycle began. XRP consolidated in a new accumulation zone between roughly $1.30 and $1.55. A fresh manipulation phase then pulled the price back toward $1.20. XRP currently sits at $1.3049, inside that manipulation phase.
In the AMD framework, manipulation is the stage in which price moves against the majority, triggering stop losses and shaking out weak holders before the next expansion begins.
The strength of Carolina’s argument lies in the back-to-back nature of the two cycles on the chart. The first AMD sequence completed and confirmed the pattern. The second is now in its final phase before expansion. Carolina presents the repetition itself as the signal.
What Comes Next?
If the second cycle follows the path of the first, distribution arrives next. Carolina’s XRP chart projects a move well above $2, beyond the $1.68 peak reached in August.
The AMD structure identifies distribution as the phase in which price expands sharply. In the first cycle, that expansion took XRP from below $1 to $1.68. Carolina’s chart marks the projected second distribution as a larger move, with the asset climbing past $2 and toward $2.30.
Carolina’s conclusion ties the whole analysis together. “XRP will soar to great heights this cycle.”
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

